Literature DB >> 31404025

18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Treatment Efficacy and Clinical Outcome for Patients With Pancreatic Carcinoma: A Meta-analysis.

Li Wang1, Ping Dong2, Guohua Shen2, Shengzhong Hou1, Yi Zhang1, Xubao Liu1, Bole Tian1.   

Abstract

OBJECTIVES: F-Fluorodeoxyglucose positron emission tomography (FDG-PET) has been an important modality for detecting malignancies. Recently, an increasing number of studies reported the utility of FDG-PET parameters in predicting clinical outcomes and treatment assessment in variety of cancers. We aimed at clarifying both the prognostic role and assessment value of FDG-PET in pancreatic carcinoma.
METHODS: We systematically searched electronic databases of PubMed, Embase, Cochrane Library, and Web of Science to identify relevant studies to conduct this meta-analysis. Comparative analyses of the pooled hazard ratio (HR) for overall survival were performed to assess the utility of FDG-PET parameters in prognosis evaluation and treatment assessment by random-effect model.
RESULTS: Twenty-three studies with 1762 patients met the inclusion criteria of this meta-analysis. The pooled results revealed that greater maximum standardized uptake value of the primary tumor was significantly correlated with poorer overall survival (HR, 1.31; 95% confidence interval, 1.15-1.50; P < 0.001). Besides, greater reduction of maximum standardized uptake value after treatments indicated significant better overall survival (HR, 0.68; 95% confidence interval, 0.47-0.98; P = 0.037).
CONCLUSIONS: F-Fluorodeoxyglucose positron emission tomography parameters might be helpful not only for predicting survival outcome but also for selecting potentially efficacious treatments in patients with pancreatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31404025     DOI: 10.1097/MPA.0000000000001375

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  5 in total

1.  Comparison of the diagnostic efficacy of 68 Ga-FAPI-04 PET/MR and 18F-FDG PET/CT in patients with pancreatic cancer.

Authors:  Zeyu Zhang; Guorong Jia; Guixia Pan; Kai Cao; Qinqin Yang; Hongyu Meng; Jian Yang; Lu Zhang; Tao Wang; Chao Cheng; Changjing Zuo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-04       Impact factor: 10.057

Review 2.  Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy.

Authors:  Martijn A van Dam; Floris A Vuijk; Judith A Stibbe; Ruben D Houvast; Saskia A C Luelmo; Stijn Crobach; Shirin Shahbazi Feshtali; Lioe-Fee de Geus-Oei; Bert A Bonsing; Cornelis F M Sier; Peter J K Kuppen; Rutger-Jan Swijnenburg; Albert D Windhorst; Jacobus Burggraaf; Alexander L Vahrmeijer; J Sven D Mieog
Journal:  Cancers (Basel)       Date:  2021-12-02       Impact factor: 6.639

3.  Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas.

Authors:  Manuel Röhrich; Patrick Naumann; Frederik L Giesel; Peter L Choyke; Fabian Staudinger; Annika Wefers; Dawn P Liew; Clemens Kratochwil; Hendrik Rathke; Jakob Liermann; Klaus Herfarth; Dirk Jäger; Jürgen Debus; Uwe Haberkorn; Matthias Lang; Stefan A Koerber
Journal:  J Nucl Med       Date:  2020-10-23       Impact factor: 10.057

Review 4.  The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review.

Authors:  Laura Evangelista; Pietro Zucchetta; Lucia Moletta; Simone Serafini; Gianluca Cassarino; Nicola Pegoraro; Francesca Bergamo; Cosimo Sperti; Diego Cecchin
Journal:  Ann Nucl Med       Date:  2021-05-28       Impact factor: 2.668

5.  Early recurrence detected by 18F-FDG PET/CT in patients with resected pancreatic ductal adenocarcinoma.

Authors:  Li Wang; Ping Dong; Weiguo Wang; Mao Li; Weiming Hu; Xubao Liu; Bole Tian
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.